|
|
Exchange: |
N/A |
Security
Type: |
Common |
Shares
Out: |
86,568,000 |
Market
Cap: |
748.81(M) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$6.31 - $20.32 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : 957 |
Guru Rank Value : 1 |
Guru Occurances : 1 |
|
|
|
|
|
|
|
Company Profile Scholar Rock is a biopharmaceutical company focused on the discovery and development of medicines for the treatment of serious diseases. Co. has progressed the development of: Apitegromab, an inhibitor of the activation of latent myostatin for the treatment of spinal muscular atrophy; SRK-181, an inhibitor of the activation of latent transforming growth factor beta-1 for the treatment of cancers that are resistant to anti-PD-(L)1 antibody therapies; selective inhibitors of the activation of transforming growth factor beta for the treatment of fibrotic diseases; and additional discovery and early preclinical programs related to the selective modulation of growth factor signaling.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
6,579,493 |
6,890,060 |
Total Buy Value |
$0 |
$0 |
$45,086,736 |
$47,551,604 |
Total People Bought |
0 |
0 |
3 |
3 |
Total Buy Transactions |
0 |
0 |
3 |
8 |
Total Shares Sold |
3,387 |
24,160 |
127,976 |
132,368 |
Total Sell Value |
$30,149 |
$216,790 |
$1,997,360 |
$2,029,305 |
Total People Sold |
2 |
4 |
5 |
6 |
Total Sell Transactions |
2 |
6 |
18 |
21 |
End Date |
2024-06-27 |
2024-03-26 |
2023-09-26 |
2022-09-26 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Myles Edward H |
COO & CFO |
|
2023-01-17 |
4 |
D |
$11.29 |
$79,503 |
D/D |
(7,043) |
147,179 |
|
- |
|
Parlavecchio Caryn |
CHRO |
|
2023-01-17 |
4 |
D |
$11.28 |
$33,096 |
D/D |
(2,934) |
75,715 |
|
- |
|
Invus Public Equities Advisors, Llc |
10% Owner |
|
2023-01-09 |
4 |
S |
$9.48 |
$10,373 |
D/D |
(1,094) |
9,027,950 |
|
17% |
|
Invus Public Equities Advisors, Llc |
10% Owner |
|
2023-01-05 |
4 |
B |
$9.33 |
$455,091 |
D/D |
48,774 |
9,029,044 |
2.45 |
-12% |
|
Invus Public Equities Advisors, Llc |
10% Owner |
|
2022-10-25 |
4 |
B |
$8.04 |
$1,047,383 |
D/D |
130,265 |
8,980,270 |
2.45 |
22% |
|
Invus Public Equities Advisors, Llc |
10% Owner |
|
2022-10-04 |
4 |
B |
$7.89 |
$520,760 |
D/D |
66,000 |
8,850,005 |
2.45 |
25% |
|
Invus Public Equities Advisors, Llc |
10% Owner |
|
2022-10-03 |
4 |
B |
$7.03 |
$238,789 |
D/D |
33,971 |
8,784,005 |
2.45 |
42% |
|
Parlavecchio Caryn |
CHRO |
|
2022-08-16 |
4 |
D |
$11.34 |
$15,887 |
D/D |
(1,401) |
78,649 |
|
- |
|
Akkaraju Srinivas |
Director |
|
2022-07-26 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
4,598,828 |
|
4% |
|
Gilman Michael |
Director |
|
2022-07-08 |
4 |
GA |
$0.00 |
$0 |
I/I |
37,459 |
37,459 |
|
- |
|
Gilman Michael |
Director |
|
2022-07-08 |
4 |
GD |
$0.00 |
$0 |
D/D |
37,459 |
0 |
|
- |
|
Samsara Biocapital, L.p. |
10% Owner |
|
2022-06-22 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
4,598,828 |
|
- |
|
Invus Public Equities Advisors, Llc |
10% Owner |
|
2022-06-22 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
8,750,034 |
|
- |
|
Nashat Amir |
Director |
|
2022-06-22 |
4 |
B |
$4.90 |
$5,870,161 |
I/I |
1,197,992 |
206,897 |
2.1 |
- |
|
Ho Junlin |
General Counsel |
|
2022-06-16 |
4 |
A |
$0.00 |
$0 |
D/D |
45,500 |
120,591 |
|
- |
|
Myles Edward H |
COO & CFO |
|
2022-06-16 |
4 |
A |
$0.00 |
$0 |
D/D |
74,750 |
154,222 |
|
- |
|
Carven Gregory John |
Chief Scientific Officer |
|
2022-06-16 |
4 |
A |
$0.00 |
$0 |
D/D |
45,500 |
128,208 |
|
- |
|
Parlavecchio Caryn |
CHRO |
|
2022-06-16 |
4 |
A |
$0.00 |
$0 |
D/D |
35,750 |
80,050 |
|
- |
|
Mahanthappa Nagesh K. |
Interim CEO and President |
|
2022-06-16 |
4 |
A |
$0.00 |
$0 |
D/D |
50,000 |
480,491 |
|
- |
|
Parlavecchio Caryn |
CHROOfficer |
|
2022-05-26 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
44,300 |
|
- |
|
Ho Junlin |
General Counsel |
|
2022-02-14 |
4 |
A |
$0.00 |
$0 |
D/D |
37,500 |
75,091 |
|
- |
|
Chyung Yung H. |
Chief Medical Officer |
|
2022-02-14 |
4 |
A |
$0.00 |
$0 |
D/D |
37,500 |
258,496 |
|
- |
|
Mahanthappa Nagesh K. |
Interim CEO and President |
|
2022-02-14 |
4 |
A |
$0.00 |
$0 |
D/D |
50,000 |
50,000 |
|
- |
|
Carven Gregory John |
Chief Scientific Officer |
|
2022-02-14 |
4 |
A |
$0.00 |
$0 |
D/D |
35,000 |
82,708 |
|
- |
|
Myles Edward H |
COO & CFO |
|
2022-02-14 |
4 |
A |
$0.00 |
$0 |
D/D |
57,500 |
79,472 |
|
- |
|
123 Records found
|
|
Page 3 of 5 |
|
|